Jefferies Names AMEC Top China Semiconductor Equipment Pick 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Street Poller Media and The Boom of the Street Interview Ad Industry 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Amazon Secures 200 MW Wind Power Deals in Sweden 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Toyota Global Sales Fall as China Demand Slumps 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time.
The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
